An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A growing number of telehealth clinics are prescribing GLP-1 drugs — the same class that includes weight-loss medicines like Ozempic and Wegovy — to treat substance use and addiction even though these drugs aren’t FDA-approved for that purpose. The report says some online providers are offering these prescriptions off-label (meaning the drug is used for something other than its official approved use) to people seeking help with alcohol, nicotine, or other drug dependencies. GLP-1 refers to a group of drugs that mimic a natural gut hormone called glucagon-like peptide-1. That hormone helps control appetite and blood sugar. Drugs in this family, like semaglutide, have become famous for helping people lose weight and for treating diabetes. They also affect brain circuits related to reward and craving, which is why some researchers have been curious about whether GLP-1 drugs might reduce addictive behaviors. The story pulls together evidence and examples rather than announcing a definitive clinical breakthrough. There are early studies and animal experiments suggesting GLP-1 drugs can reduce craving and substance use, and some small human trials are underway. But the report mainly highlights that telehealth companies are already prescribing these medications off-label to patients seeking addiction help. That means the real-world use is outpacing the large, rigorous trials that would be needed to prove safety and effectiveness for addiction across different substances and patient groups. For a regular person, this matters because it shows how medical practice can move faster than formal regulatory approval, especially with telehealth making access easier. If traditional treatments haven’t worked for someone with alcohol or opioid problems, an off-label GLP-1 prescription might feel like a hopeful option. It could also change how addiction is treated broadly if the drugs turn out to help with cravings, making medical management more common alongside counseling and social support. There are important caveats and risks. “Off-label” doesn’t mean the drug is unsafe — doctors can legally prescribe medications off-label — but it does mean the best scientific evidence for that use may be limited. GLP-1 drugs have known side effects like nausea, diarrhea, and, rarely, more serious issues with the pancreas or gallbladder. We don’t yet know long-term effects when used for addiction, whether they work the same across different substances, or which doses and treatment lengths are best. People with certain medical conditions or on certain medications may be poor candidates. Also, telehealth prescribing can vary in quality; some programs may not provide comprehensive addiction care like counseling or monitoring. Bottom line: Some telehealth providers are already prescribing GLP-1 drugs for addiction before regulators have formally approved that use; the idea is promising but still needs stronger, reliable evidence and careful medical oversight.
Source: STAT